$ cat ./records/gates-funded-monoclonal-antibody-shows-early-promise-as-a-single--2025.txt
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[RECORD.TXT] · cat --full
A Gates-funded effort to prevent malaria with a single shot showed early promise in 2025. In a first-in-human trial sponsored by the Gates Medical Research Institute, a long-acting monoclonal antibody called MAM01 protected volunteers against malaria with no serious side effects — none of those in the highest-dose group developed the parasite after deliberate exposure. The approach aims to give months of protection to the most vulnerable, especially young children and pregnant women, complementing the malaria vaccines the Gates Foundation has long funded.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Participated in World Economic Forum panel on AI and global healthcare
Next →
Gates Joins a $600 Million 'Beginnings Fund' for Mothers and Newborns as Aid Is Cut
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates Joins a $600 Million 'Beginnings Fund' for Mothers and Newborns as Aid Is Cut
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.